top of page

World Health Organization (WHO) estimates that 4.4% of the global population suffers from depressive disorder and 3.6% from anxiety disorder.
Depression and anxiety are likely to co-occur and share many symptoms and genetic factors. Despite the availability of a wide range of drugs for treating depression and anxiety, most patients fail to achieve complete and sustained remission. Selective serotonin reuptake inhibitors (SSRIs) are the current first-line treatment for depression and anxiety, but they have pronounced limitations. Notably, they have low success rates, and dela